Goldman Sachs Lowers Estimates on Illumina, But Favors MiSeq Growth Over PGM

The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.